EUROPE ANTIFUNGAL AGENTS MARKET FORECAST 2018-2026
Europe Antifungal Agents Market by Drug Types (Echinocandins, Azoles, Polyenes, Allylamines & Others) by Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis, Others) by Applications (Topical Antifungal Drugs, Oral Drugs) by Geography
The Europe antifungal drugs market is expected to flourish at a CAGR of 3.23% over the forecast period of 2018-2026. The emerging pipeline of new and developing antifungal drugs is likely to present this market with amazing growth opportunities.
The regions analyzed in the Europe antifungal agents market are UK, France, Germany, Spain, Italy, Scandinavia, Austria, Benelux, and rest of Europe. Presently, the German antifungal agents market accounts for the highest revenue share in this region. The country provides state of the art facilities in the medical sector. Also, the 2001 German Protection Against Infection Act has been a huge booster for the Europe antifungal agents market. In this report, the overall antifungal agents market is segmented on the basis of types, applications, therapeutic indications and drug types.
The major players operating in the antifungal drugs market are GlaxoSmithKline, Vertex Pharmaceuticals, Gilead, Arbor Pharmaceuticals Inc., Bayer Healthcare, Abbott Laboratories, Astellas Pharma Inc., Baxter, Sanofi- Aventis, Johnson & Johnson, Teva Pharmaceuticals, Kramer Laboratories, Merck Co, Novartis, and Pfizer
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- TROPICAL DRUGS MARKET IS THE EMERGING APPLICATION
- ASPERGILLOSIS THERAPEUTIC INDICATION IS LEADING THE MARKET
- MARKET DETERMINANTS
- MARKET DRIVERS
- POOR HYGIENE HABITS
- DEVELOPMENT OF DRUG RESISTANCE
- MARKET RESTRAINTS
- GROWING AGING POPULATION IN SOME REGIONS
- ALTERNATE TREATMENT OPTIONS
- REGULATORY ATMOSPHERE
- MARKET OPPORTUNITIES
- EMERGING PIPELINE OF NEW AND INNOVATIVE ANTIFUNGAL DRUGS
- INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
- MARKET CHALLENGES
- GROWTH AND DEVELOPMENT OF THE GENERIC ANTIFUNGAL DRUGS MARKET
- SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
- RESISTANCE TO DRUGS
- RAPIDLY CHANGING TECHNOLOGY
- MARKET DRIVERS
- MARKET SEGMENTATION
- MARKET BY DRUG TYPES 2018-2026
- SYSTEMIC AZOLES
- TOPICAL AZOLES
- SYSTEMIC POLYENES
- TOPICAL POLYENES
- SYSTEMIC ECHINOCANDINS
- SYSTEMIC ANTIMETABOLICS
- OTHER SYSTEMIC
- OTHER TOPICAL
- OTHER DRUGS TYPES
- MARKET BY THERAPEUTIC INDICATIONS 2018-2026
- ASPERGILLOSIS MARKET
- DERMATOPHYTOSIS MARKET
- CANDIDIASIS MARKET
- OTHER THERAPEUTIC INDICATION MARKET
- MARKET BY APPLICATIONS 2018-2026
- TOPICAL ANTIFUNGAL AGENTS MARKET
- ORAL DRUGS MARKET
- MARKET BY TYPES 2018-2026
- PRESCRIPTION
- OVER THE COUNTER (OTC)
- MARKET BY DRUG TYPES 2018-2026
- KEY ANALYTICS
- PORTER’S FIVE FORCE MODEL
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
- BARGAINING POWER OF BUYER
- BARGAINING POWER OF SUPPLIER
- INTENSITY OF COMPETITIVE RIVALRY
- KEY BUYING CRITERIA
- VALUE CHAIN ANALYSIS
- MANUFACTURERS
- DISTRIBUTORS
- RETAILERS
- END-USERS
- REGULATORY FRAMEWORK
- REGULATION IN EUROPE
- OPPORTUNITY MATRIX
- PORTER’S FIVE FORCE MODEL
- GEOGRAPHICAL ANALYSIS
- EUROPE
- UNITED KINGDOM (UK)
- FRANCE
- GERMANY
- SPAIN
- ITALY
- BENELUX
- SCANDINAVIA
- AUSTRIA
- REST OF EUROPE
- EUROPE
- COMPANY PROFILES
- COMPETITIVE LANDSCAPE
- MARKET SHARE ANALYSIS
- ABBOTT LABORATORIES.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- ARBOR PHARMACEUTICALS, INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- BAXTER
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- ASTELLAS PHARMA INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- BAYER HEALTHCARE
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- TEVA PHARMACEUTICALS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- GILEAD
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- GLAXOSMITHKLINE
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- JOHNSON & JOHNSON
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- KRAMER LABORATORIES
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- MERCK & CO.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- NOVARTIS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- PFIZER
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVES
- SANOFI-AVENTIS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- VERTEX PHARMACEUTICALS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC INITIATIVE
- COMPETITIVE LANDSCAPE
TABLE LIST
TABLE 1 EUROPE ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)
TABLE 2 SKIN LESIONS OCCURRING DUE TO ANTIFUNGAL INFECTION
TABLE 3 EUROPE ANTIFUNGAL AGENTS MARKET BY DRUG TYPES MARKET 2018-2026 ($ MILLION)
TABLE 4 DRUG USES OF TRIAZOLES
TABLE 5 EUROPE ANTIFUNGAL AGENTS MARKET IN SYSTEMIC AZOLES 2018-2026 ($ MILLION)
TABLE 6 EUROPE ANTIFUNGAL AGENTS MARKET IN TOPICAL AZOLES 2018-2026 ($ MILLION)
TABLE 7 EUROPE ANTIFUNGAL AGENTS MARKET IN SYSTEMIC POLYENES 2018-2026 ($ MILLION)
TABLE 8 EUROPE ANTIFUNGAL AGENTS MARKET IN TOPICAL POLYENES 2018-2026 ($ MILLION)
TABLE 9 EUROPE ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ECHINOCANDINS 2018-2026 ($ MILLION)
TABLE 10 EUROPE ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ANTIMETABOLICS 2018-2026 ($ MILLION)
TABLE 11 EUROPE ANTIFUNGAL AGENTS MARKET IN OTHER SYSTEMIC 2018-2026 ($ MILLION)
TABLE 12 EUROPE ANTIFUNGAL AGENTS MARKET IN OTHER TOPICAL 2018-2026 ($ MILLION)
TABLE 13 EUROPE ANTIFUNGAL AGENTS MARKET IN OTHER DRUGS TYPES MARKET 2018-2026 ($ MILLION)
TABLE 14 EUROPE ANTIFUNGAL AGENTS MARKET BY THERAPEUTIC INDICATIONS MARKET 2018-2026 ($ MILLION)
TABLE 15 EUROPE ANTIFUNGAL AGENTS MARKET IN ASPERGILLOSIS 2018-2026 ($ MILLION)
TABLE 16 SYMPTOMS IN THE AFFECTED AREA CAUSED BY DERMATOPHYTES
TABLE 17 EUROPE ANTIFUNGAL AGENTS MARKET IN DERMATOPHYTOSIS MARKET 2018-2026 ($ MILLION)
TABLE 18 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 19 EUROPE ANTIFUNGAL AGENTS MARKET IN CANDIDIASIS 2018-2026 ($ MILLION)
TABLE 20 EUROPE ANTIFUNGAL AGENTS MARKET IN OTHER THERAPEUTIC INDICATION 2018-2026 ($ MILLION)
TABLE 21 EUROPE ANTIFUNGAL AGENTS MARKET BY APPLICATIONS MARKET 2018-2026 ($ MILLION)
TABLE 22 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 23 ANTIFUNGAL POWDERS AND IT’S EFFECT
TABLE 24 ANTIFUNGAL OINTMENT AND IT’S EFFECT
TABLE 25 ANTIFUNGAL PASTES AND IT’S EFFECT
TABLE 26 EUROPE ANTIFUNGAL AGENTS MARKET IN TOPICAL ANTIFUNGAL AGENTS 2018-2026 ($ MILLION)
TABLE 27 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT’S EFFECTS
TABLE 28 EUROPE ANTIFUNGAL AGENTS MARKET IN ORAL DRUGS 2018-2026 ($ MILLION)
TABLE 29 EUROPE ANTIFUNGAL AGENTS MARKET BY TYPES 2018-2026 ($ MILLION)
TABLE 30 EUROPE ANTIFUNGAL AGENTS MARKET IN PRESCRIPTION 2018-2026 ($ MILLION)
TABLE 31 EUROPE ANTIFUNGAL AGENTS MARKET IN OTC 2018-2026 ($ MILLION)
TABLE 32 EUROPE ANTIFUNGAL AGENTS MARKET BY COUNTRIES 2018-2026( $ MILLION)
TABLE 33 TOTAL BURDEN OF FUNGAL INFECTIONS IN SPAIN 2016
FIGURES LIST
FIGURE 1 EUROPE ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)
FIGURE 2 TOPICAL ANTIFUNGAL AGENTS TYPES
FIGURE 3 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
FIGURE 4 VALUE CHAIN OF ANTIDEPRESSANT DRUGS
FIGURE 5 THE UNITED KINGDOM ANTIFUNGAL AGENTS MARKET 2018-2026($MILLION)
FIGURE 6 INVESTMENT MADE BY DIFFERENT AGENTS IN FRANCE 2017(%)
FIGURE 7 FRANCE ANTI-FUNGAL AGENTS MARKET 2018-2026($ MILLION)
FIGURE 8 GERMANY ANTI-FUNGAL AGENTS MARKET 2018-2026($ MILLION)
FIGURE 9 SPAIN ANTI-FUNGAL MARKET 2018-2026($ MILLION)
FIGURE 10 ITALY ANTI-FUNGAL MARKET 2018-2026($ MILLION)
FIGURE 11 BENELUX ANTI-FUNGAL MARKET 2018-2026($ MILLION)
FIGURE 12 SCANDINAVIA ANTI-FUNGAL MARKET 2018-2026($ MILLION)
FIGURE 13 AUSTRIA ANTI-FUNGAL MARKET 2018-2026($ MILLION)
FIGURE 14 REST OF EUROPE ANTI-FUNGAL MARKET 2018-2026($ MILLION)
FIGURE 15 ANTI-FUNGAL AGENT COMPANY MARKET SHARE ANALYSIS 2017 (%)
- GEOGRAPHICAL ANALYSIS
- EUROPE
- UNITED KINGDOM (UK)
- FRANCE
- GERMANY
- SPAIN
- ITALY
- BENELUX
- SCANDINAVIA
- AUSTRIA
- REST OF EUROPE
- EUROPE
- MARKET SEGMENTATION
- MARKET BY DRUG TYPES 2018-2026
- SYSTEMIC AZOLES
- TOPICAL AZOLES
- SYSTEMIC POLYENES
- TOPICAL POLYENES
- SYSTEMIC ECHINOCANDINS
- SYSTEMIC ANTIMETABOLICS
- OTHER SYSTEMIC
- OTHER TOPICAL
- OTHER DRUGS TYPES
- MARKET BY THERAPEUTIC INDICATIONS 2018-2026
- ASPERGILLOSIS MARKET
- DERMATOPHYTOSIS MARKET
- CANDIDIASIS MARKET
- OTHER THERAPEUTIC INDICATION MARKET
- MARKET BY APPLICATIONS 2018-2026
- TOPICAL ANTIFUNGAL AGENTS MARKET
- ORAL DRUGS MARKET
- MARKET BY TYPES 2018-2026
- PRESCRIPTION
- OVER THE COUNTER (OTC)
- MARKET BY DRUG TYPES 2018-2026
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.